Nurix Therapeutics, a preclinical biotech developing small molecule therapies for cancer, raised $209 million by offering 11 million shares at $19, above the narrowed range of $17 to $18. The company originally planned to offer 8.8 million shares at a range of $16 to $18, before increasing its proposed deal size on Thursday morning. At pricing, the company commands a fully diluted market value of $754 million.
Nurix Therapeutics plans to list on the Nasdaq under the symbol NRIX. J.P. Morgan, Piper Sandler, and Stifel acted as lead managers on the deal.
